Clinical Trial Detail

NCT ID NCT02472145
Title An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

acute myeloid leukemia

bone marrow cancer

myelodysplastic syndrome

Therapies

Decitabine

Decitabine + Talacotuzumab

Age Groups: adult senior

No variant requirements are available.